Share Price and Basic Stock Data
Last Updated: January 23, 2026, 8:17 pm
| PEG Ratio | -12.14 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Zydus Wellness Ltd operates within the food processing sector, focusing on bakery, dairy, and fruit products. The company’s stock price stood at ₹422, with a market capitalization of ₹13,414 Cr. Revenue from operations reported for the financial year ending March 2025 was ₹2,709 Cr, reflecting a growth trajectory from ₹2,255 Cr in March 2023. This indicates a compounded annual growth rate (CAGR) of approximately 20% over the two-year period. Quarterly sales figures demonstrate fluctuations, with the highest quarterly sales recorded at ₹913 Cr in March 2025. The company reported total sales of ₹2,886 Cr for the trailing twelve months (TTM), indicating a robust performance relative to previous years. However, sales for the quarter ended September 2023 dropped to ₹440 Cr, demonstrating volatility in revenue generation. This inconsistency may stem from seasonal demand variations or competitive pressures in the food processing industry.
Profitability and Efficiency Metrics
Zydus Wellness reported a net profit of ₹347 Cr for the financial year ending March 2025, which is an increase from ₹310 Cr in March 2023. The operating profit margin (OPM) for the same period was recorded at 14.51%, a slight decline from 15% in the previous year. The company’s return on equity (ROE) stood at 6.02%, while the return on capital employed (ROCE) was slightly higher at 6.16%. The interest coverage ratio (ICR) was strong at 32.77x, indicating the company’s ability to comfortably meet its interest obligations. However, the operating profit margin has exhibited a downward trend, falling from 20% in March 2023 to 14.51% in March 2025. This decline in margin could suggest rising operational costs or competitive pricing pressures within the sector. Additionally, the cash conversion cycle (CCC) averaged 75 days, pointing to moderate efficiency in managing working capital.
Balance Sheet Strength and Financial Ratios
Zydus Wellness has a solid balance sheet, with total assets recorded at ₹6,442 Cr as of March 2025. The company holds reserves of ₹5,608 Cr, reflecting a robust equity position. Borrowings stood at ₹188 Cr, indicating a low leverage ratio with total debt to equity at 0.03x, which is significantly below typical industry levels. This low debt profile enhances financial stability and minimizes interest burden. The price-to-book value (P/BV) ratio was reported at 1.87x, suggesting the stock is trading at a premium relative to its book value. The current ratio stood at 1.48x, indicating adequate liquidity to cover short-term liabilities. However, while the company has shown consistent growth in revenue and profit, the declining trend in operating margins raises concerns about the sustainability of profitability, necessitating close monitoring of operational efficiencies.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Zydus Wellness reveals a stable promoter holding of 69.64%, with foreign institutional investors (FIIs) accounting for 3.43% and domestic institutional investors (DIIs) holding 18.76%. The public shareholding segment comprises 8.18% of the total. The number of shareholders increased to 77,188 by September 2025, indicating growing retail investor interest. However, the slight decline in FII and DII holdings from previous quarters may reflect cautious sentiment among institutional investors. The promoter stake has remained relatively stable, which typically signals confidence in the company’s long-term prospects. As institutional ownership plays a critical role in stock performance, the dynamics of shareholding could influence market perceptions and investor confidence, particularly in a sector characterized by competitive pressures and changing consumer preferences.
Outlook, Risks, and Final Insight
The outlook for Zydus Wellness appears cautiously optimistic, bolstered by its solid revenue growth and strong balance sheet. However, the company faces risks associated with fluctuating profit margins and potential operational inefficiencies. Increased competition in the food processing sector may further exert pressure on pricing and profitability. Additionally, the company’s ability to manage its cash conversion cycle effectively will be crucial in sustaining liquidity and operational flexibility. If Zydus Wellness can enhance its operational efficiencies and stabilize profit margins, it may continue to deliver value to shareholders. Conversely, prolonged margin compression could impact investor sentiment and stock performance. Stakeholders should remain vigilant about market trends and operational strategies to navigate potential challenges while capitalizing on growth opportunities.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mishtann Foods Ltd | 462 Cr. | 4.29 | 7.79/4.21 | 1.38 | 10.9 | 0.00 % | 42.2 % | 44.1 % | 1.00 |
| Mrs Bectors Food Specialities Ltd | 6,812 Cr. | 222 | 355/209 | 50.0 | 39.6 | 0.54 % | 18.1 % | 15.6 % | 2.00 |
| Nakoda Group of Industries Ltd | 47.7 Cr. | 27.2 | 44.0/22.2 | 18.8 | 0.00 % | 8.11 % | 15.4 % | 10.0 | |
| HMA Agro Industries Ltd | 1,301 Cr. | 26.0 | 40.4/25.4 | 10.5 | 17.3 | 1.15 % | 11.8 % | 11.5 % | 1.00 |
| Himalaya Food International Ltd | 72.8 Cr. | 8.58 | 17.9/8.01 | 12.6 | 21.8 | 0.00 % | 2.29 % | 2.79 % | 10.0 |
| Industry Average | 21,357.10 Cr | 620.37 | 116.91 | 89.80 | 0.27% | 16.37% | 17.51% | 5.63 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 429 | 416 | 713 | 702 | 440 | 403 | 783 | 841 | 493 | 462 | 913 | 861 | 650 |
| Expenses | 413 | 388 | 568 | 586 | 423 | 390 | 620 | 686 | 473 | 447 | 723 | 705 | 628 |
| Operating Profit | 16 | 28 | 145 | 116 | 17 | 13 | 162 | 155 | 20 | 15 | 190 | 156 | 23 |
| OPM % | 4% | 7% | 20% | 17% | 4% | 3% | 21% | 18% | 4% | 3% | 21% | 18% | 4% |
| Other Income | 1 | 1 | -6 | -12 | 4 | 3 | 4 | 5 | 10 | 4 | 1 | 3 | -33 |
| Interest | 3 | 4 | 5 | 5 | 6 | 6 | 6 | 4 | 1 | 3 | 4 | 2 | 16 |
| Depreciation | 6 | 6 | 7 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 13 | 11 | 25 |
| Profit before tax | 8 | 19 | 126 | 93 | 9 | 4 | 154 | 152 | 24 | 10 | 173 | 145 | -51 |
| Tax % | -4% | -1% | -15% | -18% | 31% | 92% | 3% | 3% | 12% | 37% | 1% | 12% | 4% |
| Net Profit | 8 | 20 | 145 | 110 | 6 | 0 | 150 | 148 | 21 | 6 | 172 | 128 | -53 |
| EPS in Rs | 0.27 | 0.62 | 4.57 | 3.47 | 0.19 | 0.01 | 4.72 | 4.64 | 0.66 | 0.20 | 5.40 | 4.02 | -1.66 |
Last Updated: January 2, 2026, 4:41 pm
Below is a detailed analysis of the quarterly data for Zydus Wellness Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 650.00 Cr.. The value appears to be declining and may need further review. It has decreased from 861.00 Cr. (Jun 2025) to 650.00 Cr., marking a decrease of 211.00 Cr..
- For Expenses, as of Sep 2025, the value is 628.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 705.00 Cr. (Jun 2025) to 628.00 Cr., marking a decrease of 77.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 23.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Jun 2025) to 23.00 Cr., marking a decrease of 133.00 Cr..
- For OPM %, as of Sep 2025, the value is 4.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Jun 2025) to 4.00%, marking a decrease of 14.00%.
- For Other Income, as of Sep 2025, the value is -33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Jun 2025) to -33.00 Cr., marking a decrease of 36.00 Cr..
- For Interest, as of Sep 2025, the value is 16.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Jun 2025) to 16.00 Cr., marking an increase of 14.00 Cr..
- For Depreciation, as of Sep 2025, the value is 25.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.00 Cr. (Jun 2025) to 25.00 Cr., marking an increase of 14.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -51.00 Cr.. The value appears to be declining and may need further review. It has decreased from 145.00 Cr. (Jun 2025) to -51.00 Cr., marking a decrease of 196.00 Cr..
- For Tax %, as of Sep 2025, the value is 4.00%. The value appears to be improving (decreasing) as expected. It has decreased from 12.00% (Jun 2025) to 4.00%, marking a decrease of 8.00%.
- For Net Profit, as of Sep 2025, the value is -53.00 Cr.. The value appears to be declining and may need further review. It has decreased from 128.00 Cr. (Jun 2025) to -53.00 Cr., marking a decrease of 181.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is -1.66. The value appears to be declining and may need further review. It has decreased from 4.02 (Jun 2025) to -1.66, marking a decrease of 5.68.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:44 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 404 | 431 | 397 | 431 | 513 | 843 | 1,767 | 1,867 | 2,009 | 2,255 | 2,328 | 2,709 | 2,886 |
| Expenses | 319 | 331 | 305 | 331 | 387 | 658 | 1,446 | 1,522 | 1,664 | 1,918 | 2,020 | 2,329 | 2,503 |
| Operating Profit | 85 | 100 | 91 | 99 | 125 | 185 | 321 | 344 | 345 | 337 | 308 | 380 | 383 |
| OPM % | 21% | 23% | 23% | 23% | 24% | 22% | 18% | 18% | 17% | 15% | 13% | 14% | 13% |
| Other Income | 19 | 28 | 32 | 32 | 35 | 28 | -33 | -123 | 10 | -5 | -0 | 19 | -25 |
| Interest | 0 | 0 | 0 | 1 | 2 | 30 | 140 | 84 | 26 | 16 | 24 | 12 | 26 |
| Depreciation | 0 | 8 | 7 | 7 | 9 | 13 | 26 | 25 | 24 | 25 | 24 | 28 | 54 |
| Profit before tax | 104 | 120 | 117 | 124 | 150 | 171 | 121 | 112 | 306 | 291 | 260 | 359 | 278 |
| Tax % | 5% | 7% | 10% | 10% | 9% | -0% | -17% | -6% | -1% | -7% | -3% | 3% | |
| Net Profit | 98 | 111 | 105 | 111 | 137 | 171 | 142 | 119 | 309 | 310 | 267 | 347 | 253 |
| EPS in Rs | 4.94 | 5.58 | 5.28 | 5.58 | 6.85 | 5.87 | 4.92 | 3.73 | 9.71 | 9.75 | 8.39 | 10.90 | 7.96 |
| Dividend Payout % | 24% | 22% | 25% | 23% | 23% | 17% | 20% | 27% | 10% | 10% | 12% | 11% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 13.27% | -5.41% | 5.71% | 23.42% | 24.82% | -16.96% | -16.20% | 159.66% | 0.32% | -13.87% | 29.96% |
| Change in YoY Net Profit Growth (%) | 0.00% | -18.67% | 11.12% | 17.71% | 1.39% | -41.78% | 0.76% | 175.86% | -159.34% | -14.19% | 43.83% |
Zydus Wellness Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 9% |
| 3 Years: | 10% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 13% |
| 3 Years: | 2% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | 14% |
| 1 Year: | 7% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 6% |
| Last Year: | 6% |
Last Updated: September 4, 2025, 9:45 pm
Balance Sheet
Last Updated: December 4, 2025, 12:52 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 39 | 39 | 39 | 39 | 39 | 58 | 58 | 64 | 64 | 64 | 64 | 64 | 64 |
| Reserves | 286 | 367 | 439 | 518 | 652 | 3,329 | 3,403 | 4,504 | 4,780 | 5,059 | 5,294 | 5,608 | 5,642 |
| Borrowings | 0 | 0 | 0 | 25 | 25 | 1,569 | 1,519 | 550 | 387 | 297 | 329 | 188 | 3,042 |
| Other Liabilities | 99 | 102 | 89 | 100 | 112 | 503 | 610 | 548 | 461 | 413 | 462 | 582 | 1,134 |
| Total Liabilities | 425 | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,442 | 9,882 |
| Fixed Assets | 95 | 84 | 82 | 103 | 104 | 4,567 | 4,674 | 4,667 | 4,710 | 4,732 | 4,708 | 5,125 | 8,446 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 10 | 4 | 4 | 12 | 13 | 10 | 15 | 13 |
| Investments | 5 | 0 | 94 | 30 | 148 | 46 | 110 | 0 | 27 | 70 | 78 | 36 | 28 |
| Other Assets | 324 | 423 | 391 | 550 | 577 | 835 | 802 | 995 | 943 | 1,018 | 1,354 | 1,266 | 1,394 |
| Total Assets | 425 | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,442 | 9,882 |
Below is a detailed analysis of the balance sheet data for Zydus Wellness Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 64.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 64.00 Cr..
- For Reserves, as of Sep 2025, the value is 5,642.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,608.00 Cr. (Mar 2025) to 5,642.00 Cr., marking an increase of 34.00 Cr..
- For Borrowings, as of Sep 2025, the value is 3,042.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 188.00 Cr. (Mar 2025) to 3,042.00 Cr., marking an increase of 2,854.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,134.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 582.00 Cr. (Mar 2025) to 1,134.00 Cr., marking an increase of 552.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 9,882.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,442.00 Cr. (Mar 2025) to 9,882.00 Cr., marking an increase of 3,440.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 8,446.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,125.00 Cr. (Mar 2025) to 8,446.00 Cr., marking an increase of 3,321.00 Cr..
- For CWIP, as of Sep 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 15.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 36.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 8.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,394.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,266.00 Cr. (Mar 2025) to 1,394.00 Cr., marking an increase of 128.00 Cr..
- For Total Assets, as of Sep 2025, the value is 9,882.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,442.00 Cr. (Mar 2025) to 9,882.00 Cr., marking an increase of 3,440.00 Cr..
Notably, the Reserves (5,642.00 Cr.) exceed the Borrowings (3,042.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 85.00 | 100.00 | 91.00 | 74.00 | 100.00 | 184.00 | 320.00 | -206.00 | -42.00 | 40.00 | -21.00 | 192.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 2 | 1 | 3 | 3 | 6 | 42 | 24 | 18 | 26 | 34 | 44 | 49 |
| Inventory Days | 108 | 76 | 73 | 127 | 113 | 393 | 168 | 158 | 135 | 146 | 150 | 148 |
| Days Payable | 191 | 146 | 191 | 264 | 254 | 662 | 289 | 189 | 136 | 100 | 116 | 122 |
| Cash Conversion Cycle | -82 | -69 | -116 | -134 | -135 | -227 | -97 | -13 | 25 | 80 | 78 | 75 |
| Working Capital Days | -48 | -37 | -38 | -57 | -26 | -26 | -7 | -35 | -27 | 17 | 20 | 34 |
| ROCE % | 35% | 32% | 26% | 23% | 22% | 7% | 6% | 6% | 6% | 6% | 5% | 6% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Parag Parikh Flexi Cap Fund | 22,000,000 | 0.73 | 946.99 | N/A | N/A | N/A |
| Nippon India Small Cap Fund | 16,848,030 | 1.06 | 725.22 | 2,221,106 | 2025-12-08 07:42:13 | 658.54% |
| Quant Small Cap Fund | 9,033,845 | 1.29 | 388.86 | N/A | N/A | N/A |
| Nippon India Consumption Fund | 1,358,672 | 2.1 | 58.48 | 1,403,000 | 2025-12-15 00:28:01 | -3.16% |
| Quant Multi Cap Fund | 1,250,000 | 0.61 | 53.81 | N/A | N/A | N/A |
| Parag Parikh ELSS Tax Saver Fund | 1,135,555 | 0.83 | 48.88 | N/A | N/A | N/A |
| Quant ESG Integration Strategy Fund | 426,074 | 6.72 | 18.34 | 432,771 | 2025-12-15 00:28:01 | -1.55% |
| Baroda BNP Paribas India Consumption Fund | 300,000 | 0.83 | 12.91 | N/A | N/A | N/A |
| Union Value Fund | 82,500 | 0.96 | 3.55 | N/A | N/A | N/A |
| Taurus ELSS Tax Saver Fund | 54,975 | 3.05 | 2.37 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 37.00 | 41.94 | 48.78 | 48.54 | 19.55 |
| Diluted EPS (Rs.) | 37.00 | 41.94 | 48.78 | 48.54 | 19.55 |
| Cash EPS (Rs.) | 59.01 | 45.71 | 52.71 | 52.25 | 22.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 891.76 | 842.37 | 805.07 | 761.28 | 717.87 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 891.76 | 842.37 | 805.07 | 761.28 | 717.87 |
| Revenue From Operations / Share (Rs.) | 425.93 | 366.01 | 354.36 | 315.75 | 293.36 |
| PBDIT / Share (Rs.) | 61.84 | 50.64 | 53.75 | 55.81 | 55.52 |
| PBIT / Share (Rs.) | 57.37 | 46.90 | 49.82 | 52.10 | 51.57 |
| PBT / Share (Rs.) | 56.41 | 40.90 | 45.71 | 48.09 | 17.63 |
| Net Profit / Share (Rs.) | 54.54 | 41.97 | 48.78 | 48.54 | 18.66 |
| NP After MI And SOA / Share (Rs.) | 54.54 | 41.97 | 48.78 | 48.54 | 18.66 |
| PBDIT Margin (%) | 14.51 | 13.83 | 15.16 | 17.67 | 18.92 |
| PBIT Margin (%) | 13.47 | 12.81 | 14.05 | 16.50 | 17.57 |
| PBT Margin (%) | 13.24 | 11.17 | 12.89 | 15.23 | 6.01 |
| Net Profit Margin (%) | 12.80 | 11.46 | 13.76 | 15.37 | 6.36 |
| NP After MI And SOA Margin (%) | 12.80 | 11.46 | 13.76 | 15.37 | 6.36 |
| Return on Networth / Equity (%) | 6.11 | 4.98 | 6.05 | 6.37 | 2.59 |
| Return on Capital Employeed (%) | 6.40 | 5.54 | 6.16 | 6.73 | 6.70 |
| Return On Assets (%) | 5.38 | 4.34 | 5.32 | 5.42 | 2.09 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.06 |
| Total Debt / Equity (X) | 0.03 | 0.06 | 0.05 | 0.07 | 0.12 |
| Asset Turnover Ratio (%) | 0.43 | 0.38 | 0.05 | 0.04 | 0.02 |
| Current Ratio (X) | 1.48 | 1.62 | 1.31 | 1.06 | 1.10 |
| Quick Ratio (X) | 0.78 | 1.02 | 0.65 | 0.58 | 0.62 |
| Inventory Turnover Ratio (X) | 5.50 | 2.24 | 0.89 | 0.78 | 0.54 |
| Dividend Payout Ratio (NP) (%) | 9.16 | 11.91 | 10.25 | 10.30 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 8.47 | 10.93 | 9.48 | 9.57 | 0.00 |
| Earning Retention Ratio (%) | 90.84 | 88.09 | 89.75 | 89.70 | 0.00 |
| Cash Earning Retention Ratio (%) | 91.53 | 89.07 | 90.52 | 90.43 | 0.00 |
| Interest Coverage Ratio (X) | 32.77 | 13.42 | 21.27 | 13.92 | 4.22 |
| Interest Coverage Ratio (Post Tax) (X) | 29.42 | 12.71 | 20.93 | 13.11 | 3.99 |
| Enterprise Value (Cr.) | 10742.16 | 9439.42 | 10116.33 | 9760.97 | 12849.96 |
| EV / Net Operating Revenue (X) | 3.97 | 4.05 | 4.49 | 4.86 | 6.88 |
| EV / EBITDA (X) | 27.31 | 29.31 | 29.58 | 27.48 | 36.37 |
| MarketCap / Net Operating Revenue (X) | 3.92 | 4.02 | 4.37 | 4.75 | 6.72 |
| Retention Ratios (%) | 90.83 | 88.08 | 89.74 | 89.69 | 0.00 |
| Price / BV (X) | 1.87 | 1.75 | 1.93 | 1.97 | 2.75 |
| Price / Net Operating Revenue (X) | 3.92 | 4.02 | 4.37 | 4.75 | 6.72 |
| EarningsYield | 0.03 | 0.02 | 0.03 | 0.03 | 0.01 |
After reviewing the key financial ratios for Zydus Wellness Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 37.00. This value is within the healthy range. It has decreased from 41.94 (Mar 24) to 37.00, marking a decrease of 4.94.
- For Diluted EPS (Rs.), as of Mar 25, the value is 37.00. This value is within the healthy range. It has decreased from 41.94 (Mar 24) to 37.00, marking a decrease of 4.94.
- For Cash EPS (Rs.), as of Mar 25, the value is 59.01. This value is within the healthy range. It has increased from 45.71 (Mar 24) to 59.01, marking an increase of 13.30.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 891.76. It has increased from 842.37 (Mar 24) to 891.76, marking an increase of 49.39.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 891.76. It has increased from 842.37 (Mar 24) to 891.76, marking an increase of 49.39.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 425.93. It has increased from 366.01 (Mar 24) to 425.93, marking an increase of 59.92.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 61.84. This value is within the healthy range. It has increased from 50.64 (Mar 24) to 61.84, marking an increase of 11.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is 57.37. This value is within the healthy range. It has increased from 46.90 (Mar 24) to 57.37, marking an increase of 10.47.
- For PBT / Share (Rs.), as of Mar 25, the value is 56.41. This value is within the healthy range. It has increased from 40.90 (Mar 24) to 56.41, marking an increase of 15.51.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 54.54. This value is within the healthy range. It has increased from 41.97 (Mar 24) to 54.54, marking an increase of 12.57.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 54.54. This value is within the healthy range. It has increased from 41.97 (Mar 24) to 54.54, marking an increase of 12.57.
- For PBDIT Margin (%), as of Mar 25, the value is 14.51. This value is within the healthy range. It has increased from 13.83 (Mar 24) to 14.51, marking an increase of 0.68.
- For PBIT Margin (%), as of Mar 25, the value is 13.47. This value is within the healthy range. It has increased from 12.81 (Mar 24) to 13.47, marking an increase of 0.66.
- For PBT Margin (%), as of Mar 25, the value is 13.24. This value is within the healthy range. It has increased from 11.17 (Mar 24) to 13.24, marking an increase of 2.07.
- For Net Profit Margin (%), as of Mar 25, the value is 12.80. This value exceeds the healthy maximum of 10. It has increased from 11.46 (Mar 24) to 12.80, marking an increase of 1.34.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.80. This value is within the healthy range. It has increased from 11.46 (Mar 24) to 12.80, marking an increase of 1.34.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.11. This value is below the healthy minimum of 15. It has increased from 4.98 (Mar 24) to 6.11, marking an increase of 1.13.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.40. This value is below the healthy minimum of 10. It has increased from 5.54 (Mar 24) to 6.40, marking an increase of 0.86.
- For Return On Assets (%), as of Mar 25, the value is 5.38. This value is within the healthy range. It has increased from 4.34 (Mar 24) to 5.38, marking an increase of 1.04.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has decreased from 0.06 (Mar 24) to 0.03, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.43. It has increased from 0.38 (Mar 24) to 0.43, marking an increase of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.48. This value is below the healthy minimum of 1.5. It has decreased from 1.62 (Mar 24) to 1.48, marking a decrease of 0.14.
- For Quick Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 24) to 0.78, marking a decrease of 0.24.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.50. This value is within the healthy range. It has increased from 2.24 (Mar 24) to 5.50, marking an increase of 3.26.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.16. This value is below the healthy minimum of 20. It has decreased from 11.91 (Mar 24) to 9.16, marking a decrease of 2.75.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.47. This value is below the healthy minimum of 20. It has decreased from 10.93 (Mar 24) to 8.47, marking a decrease of 2.46.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.84. This value exceeds the healthy maximum of 70. It has increased from 88.09 (Mar 24) to 90.84, marking an increase of 2.75.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.53. This value exceeds the healthy maximum of 70. It has increased from 89.07 (Mar 24) to 91.53, marking an increase of 2.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 32.77. This value is within the healthy range. It has increased from 13.42 (Mar 24) to 32.77, marking an increase of 19.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 29.42. This value is within the healthy range. It has increased from 12.71 (Mar 24) to 29.42, marking an increase of 16.71.
- For Enterprise Value (Cr.), as of Mar 25, the value is 10,742.16. It has increased from 9,439.42 (Mar 24) to 10,742.16, marking an increase of 1,302.74.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.97. This value exceeds the healthy maximum of 3. It has decreased from 4.05 (Mar 24) to 3.97, marking a decrease of 0.08.
- For EV / EBITDA (X), as of Mar 25, the value is 27.31. This value exceeds the healthy maximum of 15. It has decreased from 29.31 (Mar 24) to 27.31, marking a decrease of 2.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.92. This value exceeds the healthy maximum of 3. It has decreased from 4.02 (Mar 24) to 3.92, marking a decrease of 0.10.
- For Retention Ratios (%), as of Mar 25, the value is 90.83. This value exceeds the healthy maximum of 70. It has increased from 88.08 (Mar 24) to 90.83, marking an increase of 2.75.
- For Price / BV (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has increased from 1.75 (Mar 24) to 1.87, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.92. This value exceeds the healthy maximum of 3. It has decreased from 4.02 (Mar 24) to 3.92, marking a decrease of 0.10.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Zydus Wellness Ltd:
- Net Profit Margin: 12.8%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.4% (Industry Average ROCE: 16.37%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.11% (Industry Average ROE: 17.51%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 29.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.78
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 47.3 (Industry average Stock P/E: 116.91)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.8%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Food Processing - Bakery/Dairy/Fruits/Others | Zydus Corporate Park, Ahmedabad Gujarat 382481 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Sharvil P Patel | Chairman |
| Mr. Tarun G Arora | WholeTime Director & CEO |
| Mr. Ganesh N Nayak | Non Executive Director |
| Mr. Kulin S Lalbhai | Independent Director |
| Mr. Akhil A Monappa | Independent Director |
| Mr. Srivishnu Raju Nandyala | Independent Director |
| Ms. Dharmishtaben N Raval | Independent Woman Director |
FAQ
What is the intrinsic value of Zydus Wellness Ltd?
Zydus Wellness Ltd's intrinsic value (as of 23 January 2026) is ₹393.01 which is 6.20% lower the current market price of ₹419.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹13,317 Cr. market cap, FY2025-2026 high/low of ₹531/299, reserves of ₹5,642 Cr, and liabilities of ₹9,882 Cr.
What is the Market Cap of Zydus Wellness Ltd?
The Market Cap of Zydus Wellness Ltd is 13,317 Cr..
What is the current Stock Price of Zydus Wellness Ltd as on 23 January 2026?
The current stock price of Zydus Wellness Ltd as on 23 January 2026 is ₹419.
What is the High / Low of Zydus Wellness Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Zydus Wellness Ltd stocks is ₹531/299.
What is the Stock P/E of Zydus Wellness Ltd?
The Stock P/E of Zydus Wellness Ltd is 47.3.
What is the Book Value of Zydus Wellness Ltd?
The Book Value of Zydus Wellness Ltd is 179.
What is the Dividend Yield of Zydus Wellness Ltd?
The Dividend Yield of Zydus Wellness Ltd is 0.29 %.
What is the ROCE of Zydus Wellness Ltd?
The ROCE of Zydus Wellness Ltd is 6.16 %.
What is the ROE of Zydus Wellness Ltd?
The ROE of Zydus Wellness Ltd is 6.02 %.
What is the Face Value of Zydus Wellness Ltd?
The Face Value of Zydus Wellness Ltd is 2.00.